Anbio Corp - Multiplikator Forward P/S NNNN
Anbio Biotechnology generates revenue through the supply of diagnostic systems and reagents to global medical centers. The business's forward P/S ratio shows a peak, after which the metric leveled off at 17.30. However, strict FDA oversight and logistical disruptions create risks. Meanwhile, moderate pricing power limits profitability unless the company implements unique patented developments.
Rincian metrik komprehensif lan analitis Anbio Corp (NNNN)
- rega pasar lan target rega analis:
- rincian nilai pasar emiten:
- statistik nilai buku emiten:
- rincian struktur utang lan likuiditas bisnis:
Rasio Total Utang marang Ekuitas Anbio Biotechnology|NNNN - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Anbio Biotechnology|NNNN - Utang perusahaan|Utang-utang marang kapitalisasi buku Anbio Corp|NNNN - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Anbio Biotechnology|Indikator likuiditas cepet anbio.com
- rincian asil keuangan lan kelipatan valuasi:
NNNN - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Anbio Biotechnology|NNNN - Kapitalisasi marang bathi|Pangali Forward P/E Anbio Tech|NNNN - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Anbio Corp|NNNN - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Anbio Biotechnology|NNNN - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan anbio.com|NNNN - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Anbio Biotechnology
- indikator volume dodolan lan pendapatan:
Ringkesan analitik perusahaan:Anbio NNNN
AI and robotics-driven automation of biomarker analysis is scaling revenue for Anbio Biotechnology (NNNN), which directly impacts the projected P/S trend. This indicator correlates market capitalization with forecasted sales, allowing investors to assess the premium paid for future growth and determine the asset's fair value during the intervals between official financial reports.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Agilent A|DGX: Kapitalisasi marang prakiraan pendapatan|Illumina Corp - Multiplikator Forward P/S|EXAS: Rasio rega marang prakiraan pendapatan|RVTY: Multiplikator Forward P/S|BIO - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Sotera Health|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Quidel Corporation QDEL|Multiplikator forward rega marang pendapatan OPK (OPKO Corp)|CDNA (CareDx Health) - Rega forward marang dodolan|Multiplikator Forward P/S MRVI (Maravai LifeSciences)|fulgentgenetics.com - Rasio rega marang prakiraan pendapatan|Standard BioTools - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Cytek Biosciences Inc CTKB|OraSure Technologies Inc (OSUR) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Exagen (XGN)|Multiplikator forward rega marang pendapatan MDXH|LUCD (luciddx.com) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S PRE|IMDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S TRIB (Trinity Biotech)|PRPH - Multiplikator forward rega marang pendapatan|Ainos, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan CODX (codiagnostics.com)|HeartSciences (HSCS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan BMRA|Rasio rega marang prakiraan pendapatan Cardio Diagnostics Holdings Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Onconetix Corporation ONCO|Rasio rega marang prakiraan pendapatan Virax Biolabs Group (VRAX)|Rasio rega marang prakiraan pendapatan BJDX (bluejaydx.com)|Rasio rega marang prakiraan pendapatan Aspira Women's Health Inc. AWH|Accelerate Diagnostics Inc. (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Enzo Biochem, Inc. (ENZ)|FRES (fresh2.co) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Genetic Technologies Limited (GENE)|Rasio rega marang prakiraan pendapatan 23andMe|Kapitalisasi marang prakiraan pendapatan PMD (Psychemedics Corp.)
